Abstract 2134P
Background
Hodgkin’s lymphoma survivors (HLSs) are at risk for late effects due to their early age at diagnosis, multimodal therapy and long life expectancy. Among HLSs, we explored self-reported late effects, and assessed their information needs regarding lifestyle (diet and physical activity) and rehabilitation, in addition to need for long-term follow-up and factors associated with these needs.
Methods
HLSs treated 1997-2006 and aged 18-49 years at diagnosis were identified by the Norwegian Cancer Registry and invited to participate in this population-based, cross-sectional study consisting of a questionnaire, blood tests, clinical examination and echocardiography. Information regarding histology, stage and treatment was retrieved from medical records. Descriptive statistics and logistic regression models were used.
Results
Among the participants (n=304, 59% response rate), median age at diagnosis was 29 years (range 8-49), median age at survey 45 years (21-70), median observation time 16 years (10-22) and 48 % were females. Ninety percent had classical HL, 62% had stage I-IIA disease, 94% received chemotherapy and 77% radiotherapy. Seventy-four percent reported to have experienced ≥1 late effects; concentration/memory problems (29%), numbness/nerve pain (32%) and dental problems (27%) were the most common. Forty-one percent reported chronic fatigue (CF). One third reported to have received follow-up for late effects. A total of 64% wanted information about lifestyle and/or rehabilitation, and 58% wanted regularly follow-up for late effects. In the multivariable models, CF (OR 2.2, 95%CI 1.2-4.1), short education (2.2, 1.2-4.0), being physical inactive (2.0, 1.1-3.5) were associated with increased likelihood of need for information about lifestyle and/or rehabilitation. CF was associated with increased likelihood of need for follow-up for late effects (2.1, 1.3-3.6).
Conclusions
HLSs report a high level of late effects and only a small proportion receive follow-up for these problems. Chronic fatigue is associated with need for information and follow-up, indicating that these patients could benefit from a more structured model for long-term follow-up than what is currently available.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426; Norwegian Extra Foundation for Health and Rehabilitation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07